قرص آملودیپین در درمان فشاری خون بالا، درمان آنژین پایدار مزمن و علامتی، درمان آنژین ناشی از تنگ شدن عروق که تائید شده یا مشکوک است (پرینزمتال)، جلوگیری از بستری شدن بیمار قلبی-عروقی که بیماری آن اثبات شده (این مورد محدود به بیماران بدون سابقه ایست قلبی و یا میزان پمپاژ خون کمتر از ۴۰% می باشد) تجویز می گردد.
For use when treatment with both amlodipine and atorvastatin is appropriate:
Amlodipine: Management of hypertension; treatment of chronic stable angina, vasospastic angina (confirmed or suspected); to reduce the risk of hospitalization for angina and to reduce risk of coronary revascularization procedure due to angina with documented CAD (without heart failure or ejection fraction <40%)
Atorvastatin: Treatment of dyslipidemias or primary prevention of cardiovascular disease (atherosclerotic) as detailed here:
Primary prevention of cardiovascular disease (high-risk for cardiovascular disease [CVD]): To reduce the risk of MI, stroke, and revascularization procedures and angina in adults without clinically evident coronary heart disease (CHD) who have multiple CHD risk factors (eg, age, smoking, hypertension, low high-density lipoprotein cholesterol [HDL-C], family history of early CHD); to reduce the risk of MI and stroke in patients with type 2 diabetes and without clinically evident CHD but with multiple risk factors for CHD (eg, retinopathy, albuminuria, smoking, hypertension)
Secondary prevention of cardiovascular disease: To reduce the risk of nonfatal MI, fatal and nonfatal stroke, revascularization procedures, hospitalization for heart failure, and angina in patients with clinically evident CHD
Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) according to the American College of Cardiology/American Heart Association: To reduce the risk of ASCVD in patients with clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin); in patients without clinical ASCVD if LDL-C is ≥190 mg/dL; in patients without clinical ASCVD who have type 1 or type 2 diabetes and are between 40 and 75 years of age; in patients with an estimated 10-year ASCVD risk ≥7.5% and who are between 40 and 75 years of age (Stone 2013). Specific recommendations from the Kidney Disease: Improving Global Outcomes (KDIGO) organization have also been released for patients with chronic kidney disease (KDIGO [Tonelli 2013]).
Dyslipidemias: To reduce elevations in total cholesterol, LDL-C, apolipoprotein B (apo B), and triglycerides (TG), and to increase low HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson type IIa and IIb hyperlipidemias); treatment of primary dysbetalipoproteinemia (Fredrickson type III), elevated serum TG levels (Fredrickson type IV), and homozygous familial hypercholesterolemia
Heterozygous familial hypercholesterolemia (HeFH): Management of HeFH in adolescent patients (10 to 17 years of age; postmenarche females) having LDL-C ≥190 mg/dL or LDL-C ≥160 mg/dL with positive family history of premature cardiovascular disease (CVD) or LDL-C ≥160 mg/dL with two or more CVD risk factors.
قرص هیدروکلروتیازید در دسته مدرهای تیازیدی است و کاربرد اصلی آن در درمان فشار خون، درمان ورم در هنگام نارسایی قلبی یا کلیوی می باشد.
والزارتان به تنهایی یا به همراه سایر داروهای کاهنده ی فشار خون مانند لوزارتان و هیدروکلروتیازید جهت درمان و کنترل پرفشاری خون مورد استفاده قرار می گیرد.
مصرف والزارتان موجب کاهش ریسک مرگ و میر در بیماران مبتلا به نارسایی بطن چپ، پس از سکته های قلبی می شود. (درمان نارسایی قلبی کلاس 2 تا 4 در طبقه بندی NYHA)